vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and MANHATTAN BRIDGE CAPITAL, INC (LOAN). Click either name above to swap in a different company.
MANHATTAN BRIDGE CAPITAL, INC is the larger business by last-quarter revenue ($2.1M vs $1.6M, roughly 1.3× Atara Biotherapeutics, Inc.). On growth, MANHATTAN BRIDGE CAPITAL, INC posted the faster year-over-year revenue change (-9.1% vs -95.1%). Over the past eight quarters, MANHATTAN BRIDGE CAPITAL, INC's revenue compounded faster (-8.0% CAGR vs -75.9%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Manhattan Bridge Capital, Inc. is a U.S.-based real estate finance firm that provides short-term asset-backed secured loans primarily to real estate investors. Its core offerings include bridge loans for residential and commercial property acquisitions, rehabilitation, and refinancing, serving clients across key U.S. real estate markets.
ATRA vs LOAN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $2.1M |
| Net Profit | — | $1.3M |
| Gross Margin | — | — |
| Operating Margin | — | 61.4% |
| Net Margin | — | 61.6% |
| Revenue YoY | -95.1% | -9.1% |
| Net Profit YoY | 73.2% | -7.2% |
| EPS (diluted) | — | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1M | ||
| Q4 25 | $1.6M | $2.0M | ||
| Q3 25 | $3.5M | $2.0M | ||
| Q2 25 | $17.6M | $2.4M | ||
| Q1 25 | $98.1M | $2.3M | ||
| Q4 24 | $32.8M | $2.4M | ||
| Q3 24 | $40.2M | $2.3M | ||
| Q2 24 | $28.6M | $2.4M |
| Q1 26 | — | $1.3M | ||
| Q4 25 | — | $1.1M | ||
| Q3 25 | $-4.3M | $1.2M | ||
| Q2 25 | $2.4M | $1.4M | ||
| Q1 25 | $38.0M | $1.4M | ||
| Q4 24 | $-12.7M | $1.3M | ||
| Q3 24 | $-21.9M | $1.4M | ||
| Q2 24 | $-19.0M | $1.4M |
| Q1 26 | — | 61.4% | ||
| Q4 25 | — | 55.9% | ||
| Q3 25 | -103.5% | 58.8% | ||
| Q2 25 | 18.2% | 59.9% | ||
| Q1 25 | 39.5% | 60.2% | ||
| Q4 24 | -37.3% | 55.2% | ||
| Q3 24 | -54.1% | 60.3% | ||
| Q2 24 | -63.7% | 57.5% |
| Q1 26 | — | 61.6% | ||
| Q4 25 | — | 56.1% | ||
| Q3 25 | -124.6% | 59.1% | ||
| Q2 25 | 13.6% | 60.0% | ||
| Q1 25 | 38.7% | 60.4% | ||
| Q4 24 | -38.8% | 55.4% | ||
| Q3 24 | -54.5% | 60.5% | ||
| Q2 24 | -66.5% | 57.7% |
| Q1 26 | — | $0.11 | ||
| Q4 25 | — | $0.10 | ||
| Q3 25 | $-0.32 | $0.11 | ||
| Q2 25 | $0.19 | $0.12 | ||
| Q1 25 | $3.50 | $0.12 | ||
| Q4 24 | $0.27 | $0.12 | ||
| Q3 24 | $-2.93 | $0.12 | ||
| Q2 24 | $-3.10 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $43.1M |
| Total Assets | $20.2M | $64.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.5M | — | ||
| Q3 25 | $13.7M | — | ||
| Q2 25 | $22.3M | — | ||
| Q1 25 | $13.8M | — | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $35.3M | — |
| Q1 26 | — | $43.1M | ||
| Q4 25 | $-38.5M | $43.1M | ||
| Q3 25 | $-36.6M | $43.3M | ||
| Q2 25 | $-35.0M | $43.4M | ||
| Q1 25 | $-55.1M | $43.3M | ||
| Q4 24 | $-97.3M | $43.3M | ||
| Q3 24 | $-90.5M | $43.3M | ||
| Q2 24 | $-110.9M | $43.2M |
| Q1 26 | — | $64.3M | ||
| Q4 25 | $20.2M | $62.4M | ||
| Q3 25 | $30.2M | $60.0M | ||
| Q2 25 | $36.9M | $67.6M | ||
| Q1 25 | $62.0M | $65.8M | ||
| Q4 24 | $109.1M | $67.4M | ||
| Q3 24 | $142.7M | $70.7M | ||
| Q2 24 | $117.3M | $68.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $1.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 0.99× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3M | ||
| Q4 25 | $-50.9M | $4.9M | ||
| Q3 25 | $-9.8M | $1.4M | ||
| Q2 25 | $-7.3M | $1.2M | ||
| Q1 25 | $-28.1M | $1.2M | ||
| Q4 24 | $-24.5M | $4.9M | ||
| Q3 24 | $-4.0M | $1.2M | ||
| Q2 24 | $-10.6M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $4.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-24.6M | $4.9M | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | $-10.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 246.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -75.0% | 208.9% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | -37.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | 0.2% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | 0.99× | ||
| Q4 25 | — | 4.39× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | -3.07× | 0.87× | ||
| Q1 25 | -0.74× | 0.86× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
